Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Radar on Market Access: IngenioRx Drug Trend Report

Posted by Matt Breese on Jun 12, 2018

IngenioRx, the PBM being developed by Anthem, Inc., released a drug trend report on May 31 that illustrates how it plans to stand out in a rapidly changing PBM landscape: by analyzing and managing the cost of drugs prescribed to consumers through both their medical and pharmacy benefits, AIS Health reported.

"That’s a key differential in our report that you're not going to see anywhere else, and the numbers aren't going to match up and compare, because those competitors aren’t considering medical drug spend," says Colleen Haines, Anthem's president of clinical and specialty pharmacy.

Read More

Topics: Specialty, Industry Trends, Data & Analytics

MMIT Reality Check on Chronic Lymphocyctic Leukemia

Posted by Matt Breese on May 31, 2018

According to our recent payer coverage analysis for CLL treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on Atopic Dermatitis (May 2018)

Posted by Matt Breese on May 31, 2018

According to our recent payer coverage analysis for atopic dermatitis, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on Psoriasis (Q2 2018)

Posted by Matt Breese on May 18, 2018

According to our recent payer coverage analysis for psoriasis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

MMIT Reality Check on Hypertension (Q2 2018)

Posted by Matt Breese on May 11, 2018

According to our recent payer coverage analysis for hypertension treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

MMIT Reality Check on Respiratory (Asthma/COPD) (May 2018)

Posted by Matt Breese on May 2, 2018

According to our recent payer coverage analysis for asthma and COPD treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

Radar on Market Access: Specialty Drug Spend

Posted by Matt Breese on Apr 26, 2018

The United States saw a 0.6% increase in net spending on medications to $324 billion last year, AIS Health reported based on IQVIA Institute for Human Data Science’s report.

Those numbers represent "the amount being received by pharmaceutical manufacturers net of rebates, off-invoice discounts and other concessions," said Murray Aitken, executive director of the institute. But on an invoice basis, total spending was $453 billion, according to Medicine Use and Spending in the U.S.: A Review of 2017 and Outlook to 2022.

Read More

Topics: Specialty, Industry Trends, Data & Analytics

MMIT Reality Check on Viscosupplements (Apr 2018)

Posted by Matt Breese on Apr 20, 2018

According to our recent payer coverage analysis for viscosupplements, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

Radar On Market Access: New Financing Strategies for Innovative Therapies

Posted by Matt Breese on Apr 17, 2018

While breakthrough clinical treatments have the potential to change patients’ lives, their high upfront costs raise tricky questions for payers. A recent webinar hosted by the National Pharmaceutical Council explored some potential solutions to these financing challenges, AIS Health reported.
 
Finding a realistic and workable financing mechanism is important for patients, as the price tag for some new therapies is indeed steep. 
 
Read More

Topics: Specialty, Industry Trends, Market Access, Payer

MMIT Reality Check on Hepatitis C (Apr 2018)

Posted by Matt Breese on Apr 12, 2018

According to our recent payer coverage analysis for Hepatitis C treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing